Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses

ABSTRACT Human infections with avian influenza viruses are a serious public health concern. The neuraminidase (NA) inhibitors (NAIs) are the frontline anti-influenza drugs and are the major option for treatment of newly emerging influenza. Therefore, it is essential to identify the molecular markers of NAI resistance among specific NA subtypes of avian influenza viruses to help guide clinical management. NAI-resistant substitutions in NA subtypes other than N1 and N2 have been poorly studied. Here, we identified NA amino acid substitutions associated with NAI resistance among influenza viruses of N3, N7, and N9 subtypes which have been associated with zoonotic transmission. We applied random mutagenesis and generated recombinant influenza viruses carrying single or double NA substitution(s) with seven internal genes from A/Puerto Rico/8/1934 (H1N1) virus. In a fluorescence-based NA inhibition assay, we identified three categories of NA substitutions associated with reduced inhibition by NAIs (oseltamivir, zanamivir, and peramivir): (i) novel subtype-specific substitutions in or near the enzyme catalytic site (R152W, A246T, and D293N, N2 numbering), (ii) subtype-independent substitutions (E119G/V and/or D and R292K), and (iii) substitutions previously reported in other subtypes (Q136K, I222M, and E276D). Our data show that although some markers of resistance are present across NA subtypes, other subtype-specific markers can only be determined empirically. IMPORTANCE The number of humans infected with avian influenza viruses is increasing, raising concerns of the emergence of avian influenza viruses resistant to neuraminidase (NA) inhibitors (NAIs). Since most studies have focused on NAI-resistance in human influenza viruses, we investigated the molecular changes in NA that could confer NAI resistance in avian viruses grown in immortalized monolayer cells, especially those of the N3, N7, and N9 subtypes, which have caused human infections. We identified not only numerous NAI-resistant substitutions previously reported in other NA subtypes but also several novel changes conferring reduced susceptibility to NAIs, which are subtype specific. The findings indicate that some resistance markers are common across NA subtypes, but other markers need to be determined empirically for each subtype. The study also implies that antiviral surveillance monitoring could play a critical role in the clinical management of influenza virus infection and an essential component of pandemic preparedness.

[1]  R. Webster,et al.  Continuing challenges in influenza , 2014, Annals of the New York Academy of Sciences.

[2]  Weizhong Yang,et al.  Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study , 2014, The Lancet.

[3]  J. Järhult,et al.  Study of Oseltamivir and Zanamivir Resistance-Related Mutations in Influenza Viruses Isolated from Wild Mallards in Sweden , 2014, PloS one.

[4]  Weizhong Yang,et al.  Epidemiology of human infections with avian influenza A(H7N9) virus in China. , 2014, The New England journal of medicine.

[5]  T. Mettenleiter,et al.  Prevalence and control of H7 avian influenza viruses in birds and humans , 2014, Epidemiology and Infection.

[6]  Adolfo García-Sastre,et al.  Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility , 2013, Nature Communications.

[7]  Ha T. Nguyen,et al.  Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria , 2013, Influenza and other respiratory viruses.

[8]  Yufei Wang,et al.  High severity and fatality of human infections with avian influenza A(H7N9) infection in China. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Zheng Zhu,et al.  A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus , 2013, Virus Research.

[10]  X. Kan,et al.  Origin and molecular characteristics of a novel 2013 avian influenza A(H6N1) virus causing human infection in Taiwan. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Jianhua He,et al.  Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses , 2013, Cell Research.

[12]  T. Tumpey,et al.  Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice , 2013, Nature.

[13]  M. Peiris,et al.  Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance , 2013, The Lancet.

[14]  Weizhong Yang,et al.  Detection of mild to moderate influenza A/H7N9 infection by China’s national sentinel surveillance system for influenza-like illness: case series , 2013, BMJ.

[15]  Bin Cao,et al.  Human infection with avian influenza A H7N9 virus: an assessment of clinical severity , 2013, The Lancet.

[16]  C. Davis,et al.  Pathogenesis, Transmissibility, and Ocular Tropism of a Highly Pathogenic Avian Influenza A (H7N3) Virus Associated with Human Conjunctivitis , 2013, Journal of Virology.

[17]  Ha T. Nguyen,et al.  Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. , 2013, Antiviral research.

[18]  M. Imai,et al.  A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. , 2012, Biochemical and biophysical research communications.

[19]  David W. Smith,et al.  Characteristics of a Widespread Community Cluster of H275Y Oseltamivir-Resistant A(H1N1)pdm09 Influenza in Australia , 2012, The Journal of infectious diseases.

[20]  R. Webster,et al.  Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir. , 2012, Antiviral research.

[21]  Erhard van der Vries,et al.  Multidrug Resistant 2009 A/H1N1 Influenza Clinical Isolate with a Neuraminidase I223R Mutation Retains Its Virulence and Transmissibility in Ferrets , 2011, PLoS pathogens.

[22]  Samir N. Patel,et al.  Multidrug-Resistant Pandemic (H1N1) 2009 Infection in Immunocompetent Child , 2011, Emerging infectious diseases.

[23]  G. Boivin,et al.  Influenza drug resistance. , 2011, Seminars in respiratory and critical care medicine.

[24]  David W. Smith,et al.  Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[25]  R. Webster,et al.  Oseltamivir-resistant Influenza A and B Viruses Pre- and Postantiviral Therapy in Children and Young Adults With Cancer , 2011, The Pediatric infectious disease journal.

[26]  Arjun Srinivasan,et al.  Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009. , 2011, The Journal of infectious diseases.

[27]  C. Wolfe,et al.  Pandemic (H1N1) 2009 and Oseltamivir Resistance in Hematology/Oncology Patients , 2010, Emerging infectious diseases.

[28]  Ha T. Nguyen,et al.  Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  I. Barr,et al.  Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. , 2010, Antiviral research.

[30]  Ha T. Nguyen,et al.  Assessment of Pandemic and Seasonal Influenza A (H1N1) Virus Susceptibility to Neuraminidase Inhibitors in Three Enzyme Activity Inhibition Assays , 2010, Antimicrobial Agents and Chemotherapy.

[31]  L. Gubareva,et al.  Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance , 2010, Antimicrobial Agents and Chemotherapy.

[32]  R. Webster,et al.  Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. , 2010, The Journal of general virology.

[33]  R. Saito,et al.  Rare Influenza A (H3N2) Variants with Reduced Sensitivity to Antiviral Drugs , 2010, Emerging infectious diseases.

[34]  P. Horby,et al.  A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. , 2010, The New England journal of medicine.

[35]  I. Barr,et al.  In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza Viruses , 2009, Antimicrobial Agents and Chemotherapy.

[36]  A. Kelso,et al.  Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation , 2009, Journal of Virology.

[37]  C. Bridges,et al.  Past, Present, and Possible Future Human Infection with Influenza Virus A Subtype H7 , 2009, Emerging infectious diseases.

[38]  J. Peiris,et al.  Avian influenza viruses in humans. , 2009, Revue scientifique et technique.

[39]  Guy Boivin,et al.  A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus. , 2009, The Journal of infectious diseases.

[40]  Larisa V. Gubareva,et al.  Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 , 2008, Antimicrobial Agents and Chemotherapy.

[41]  T. Tumpey,et al.  Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility , 2008, Proceedings of the National Academy of Sciences.

[42]  I. Barr,et al.  Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues. , 2007, Antiviral research.

[43]  G. Boivin,et al.  Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  Guy Boivin,et al.  Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds , 2006, Antiviral therapy.

[45]  Janet Daly,et al.  Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. , 2006, The Journal of antimicrobial chemotherapy.

[46]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[47]  R. Webster,et al.  Importance of Neuraminidase Active-Site Residues to the Neuraminidase Inhibitor Resistance of Influenza Viruses , 2006, Journal of Virology.

[48]  Vasiliy P. Mishin,et al.  Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[49]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[50]  Maria Zambon,et al.  Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. , 2005, The Journal of infectious diseases.

[51]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.

[52]  Martin Hirst,et al.  Human Illness from Avian Influenza H7N3, British Columbia , 2004, Emerging infectious diseases.

[53]  A. Osterhaus,et al.  For Personal Use. Only Reproduce with Permission from the Lancet , 2022 .

[54]  Marion Koopmans,et al.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Mendel,et al.  Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir , 2002, Antimicrobial Agents and Chemotherapy.

[56]  R. Webster,et al.  A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Webster,et al.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. , 1998, The Journal of infectious diseases.

[58]  Paul W Smith,et al.  Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. , 1998, Structure.

[59]  W G Laver,et al.  Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. , 1998, Journal of medicinal chemistry.

[60]  J. Banks,et al.  Avian influenza virus isolated from a woman with conjunctivitis , 1996, The Lancet.

[61]  P. Colman.  Influenza virus neuraminidase: Structure, antibodies, and inhibitors , 1994, Protein science : a publication of the Protein Society.

[62]  L. Kit,et al.  A revision of the system of nomenclature for influenza viruses: a WHO memorandum. , 1980, Bulletin of the World Health Organization.

[63]  M. Potier,et al.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.

[64]  Ha T. Nguyen,et al.  Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. , 2012, Antiviral therapy.

[65]  Guy Boivin,et al.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. , 2011, The Journal of infectious diseases.

[66]  C. Fegan,et al.  Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. , 2011, The Journal of infectious diseases.

[67]  L. Brammer,et al.  Update: influenza activity - United States, September 28, 2008--January 31, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[68]  Tanja Popovic,et al.  Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[69]  J. S. Malik Peiris.  Avian influenza viruses in humans. , 2009, Revue scientifique et technique.

[70]  B. Lina,et al.  Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[71]  High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season. , 2006, MMWR. Morbidity and mortality weekly report.

[72]  R. Sidwell,et al.  Influenza virus resistance to neuraminidase inhibitors. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[73]  Update: influenza activity--United States. , 1986, MMWR. Morbidity and mortality weekly report.